Published in final edited form as:

J Org Chem. 2009 February 20; 74(4): 1509–1516. doi:10.1021/jo802211n.

Synthesis of Conformationally Preorganized and Cell-Permeable Guanidine-Based γ -Peptide Nucleic Acids (γ GPNA)s

Bichismita Sahu¹, Venugopal Chenna¹, Kira L. Lathrop², Sufi M. Thomas³, Gerald Zon⁴, Kenneth J. Livak⁴, and Danith H. Ly^{1,*}

¹ Department of Chemistry and Center for Nucleic Acids Science and Technology, Carnegie Mellon University, 4400 Fifth Avenue, Pittsburgh, Pennsylvania 15213; ² Eye and Ear Institute, University of Pittsburgh, 203 Lothrop Street, Pittsburgh, Pennsylvania 15261; ³ Department of Otolaryngology, University of Pittsburgh, 200 Lothrop Street, Pittsburgh, Pennsylvania 15213 and ⁴ Applied Biosystems, 850 Lincoln Centre Drive, Foster City, California 94404

Abstract

A general method for preparing optically-pure guanidine-based γ -peptide nucleic acid (γ GPNA) monomers for all four natural nucleobases (A, C, G and T) is described. These second-generation γ GPNA)s differ from the first in that the guanidinium group is installed at the γ -instead of the α -position of the *N*-(2-aminoethyl)glycine backbone unit. This positional switch enables GPNA)s to be synthesized from relatively cheap L- as opposed to D-amino acids. Unlike their α -predecessors, which are randomly-folded, γ GPNA)s prepared from L-amino acids are preorganized into a right-handed helix and bind to DNA and RNA with exceptionally high affinity and sequence selectivity, and are readily taken up by mammalian cells.

Introduction

One of the major challenges facing antisense and antigene technology is cellular delivery. Several classes of oligonucleotides have been developed that can recognize and bind to DNA and RNA with high affinity and sequence selectivity, and withstand enzymatic degradation by proteases and nucleases; however, few can traverse the cell membrane on their own.^{1–4} Additional chemical, mechanical and/or electrical transduction means are generally employed to transport these oligonucleotides into cells.^{5,6} While this may be a viable option for small-scale experimental setups, it is not practical for many *in vivo* experiments, and therapeutic and diagnostic applications. Aside from the technical challenge, the use of such exogenous transduction reagents/means can lead to off-target and cytotoxic effects.⁷ It is therefore essential to be able to modify the structures and/or chemical functionalities of these oligonucleotides further so that their cellular uptake and other desired features can be augmented and/or improved upon without the need for auxiliary transduction reagents/means.

Peptide nucleic acid (PNA) is a particularly promising class of nucleic acid mimics, developed in the last decade, in which the natural sugar-phosphodiester backbone has been replaced by the achiral *N*-(2-aminoethyl)glycine units.⁸ The neutral backbone allows PNA to hybridize to DNA and RNA with high affinity (and sequence selectivity) through Watson-Crick base-pairing, while the unnatural polyamide linkage allows PNA to withstand enzymatic

dly@andrew.cmu.edu.

Present address: Venugopal Chenna, Department of Oncology, John Hopkins Medical Institutes, Baltimore, Maryland 21231

degradation by proteases and nucleases.³ These properties, along with the ease of its synthesis, have made PNA an attractive reagent for many applications in chemistry, biology and medicine.⁹ However, the full potential of PNA has not yet been fully realized due, in large part, to its poor cellular uptake properties¹⁰—although some progress has been made in recent years.¹¹

Inspired by the facile uptake of HIV-1 TAT protein,^{12,13} and related peptides^{14–16} and peptidomimetics,^{17,18} we have recently shown that covalent attachment of arginine side-chain to the α -position of *N*-(2-aminoethyl)glycine backbone unit enables PNAs (GPNAs) to get into cells.^{19–21} This design differs from the conventional conjugation approach in that the recognition and transduction elements are integrated into a single unit. This strategy requires fewer coupling steps in the oligomer synthesis and minimizes the amphiphatic character of the oligonucleotides, making them less disruptive to the cell membrane and therefore less toxic to the cells.²² The ability of these oligomers to traverse the cell membrane and bind to their designated RNA targets has already been demonstrated in our recent studies, in which we showed potent and selective inhibition of E-cadherin gene expression in mammalian cells²³ and, in the systemic delivery and treatment of squamous cell carcinoma (SCCHN) xenograph model (data not shown). Although these results are promising, GPNAs cannot be prepared in large scale for clinical testing because of the high cost associated with monomer synthesis. They need to be prepared from relatively expensive D-amino acids because the L-configuration does not allow them to bind effectively to DNA or RNA.²¹ In this *Article*, we report the synthesis of the second-generation GPNAs, which can be prepared from relatively cheap L-amino acids and exhibit favorable hybridization and cellular uptake properties. As single strands, these γ GPNA oligomers are already preorganized into a right-handed helix and bind to DNA and RNA with high affinity and sequence selectivity, and are readily taken up by mammalian cells.

Results and Discussion

Monomer synthesis

The γ GPNA monomers for all four natural nucleobases (A, C, G and T) were prepared according to the procedures outlined in Scheme 1. Boc-L-Lysine was selected as a starting material for the synthesis over Boc-L-ornithine and suitably protected Boc-L-Arg(di-Z), which are also commercially available, based purely on cost—although Wender and coworkers¹⁷ showed that an extension in the side-chain length can have a beneficial effect on cellular uptake. Boc-L-lysine was first functionalized with *N,N'*-Z-1-guanylpzazole. Reduction of the activated ester of intermediate (**2**) with NaBH₄, followed by Mitsunobu coupling with 2-(2,4-dinitrophenylsulfonamido)acetate (**4**) afforded a stable, fully-protected backbone (**5**) that can be stored over a prolonged period. We selected Mitsunobu reaction over reductive amination, a method previously used to prepare other γ PNAs,^{24–29} because of the enantioselective nature of this coupling reaction.³⁰ Instead of generating an aminoaldehyde, which is known to undergo epimerization,^{31,32} the amino acid is converted into an aminoalcohol (**3**) in the second step. This chemical transformation renders the α -proton inert to deprotonation by the base, which is the source of racemization. Removal of the dinitrosulfonate protecting group, followed by standard DCC-mediated coupling with the carboxymethylnucleobase³³ and hydrolysis yielded the desired monomers (**8a–d**).

Enantiomeric excess (ee) determination

The optical purities of the monomers were determined by ¹⁹F-NMR. Prior to analysis, the Boc-protecting group was first removed with TFA (with 5% *m*-cresol) and then coupled with chiral shift reagent, (R)-(+)- α -methoxy- α -(trifluoromethyl)phenylacetyl chloride (MTPA-Cl) (Scheme 2).³⁴ Figure 1 shows the representative ¹⁹F-NMR spectra of thymine (T) γ GPNA

monomers prepared from Boc-protected D- and L-lysine following identical reaction conditions. No trace quantity of racemic mixture was observed within the detection limit of ^{19}F -NMR, which was determined to be $\sim 0.5\%$ ee.

To determine the effect of γ -backbone modification on the conformations and hybridization properties of PNAs, we synthesized a series of oligomers where the new building blocks were strategically incorporated with varying number and spatial arrangements (Table 1) and characterized their properties by CD and UV-vis spectroscopic techniques. The oligomers were synthesized manually on MBHA resins according to standard procedures.³⁵ After cleavage and removal of the protecting groups, the oligomers were purified to greater than 95% homogeneity by reverse-phase HPLC and characterized by MALDI-TOF mass spectrometry.

Conformational analysis

CD measurements were performed for PNA (PNA1) and γ GPNA (γ GPNA1 through 5) oligomers at 5 μM strand concentration each in 10 mM sodium phosphate buffer (pH 7.4) at room temperature (Figure 2). No CD signals were observed for PNA1 in the nucleobase absorption regions (220–320 nm). This result indicates one of two possibilities—either that it does not adopt helical information (absence of base-stacking), or that it does adopt helical conformation but with an equal proportion of a right- and left-handed helix, as suggested by MD simulations.³⁶ We ruled out the second possibility based on 2D-NMR analysis.³⁷ In addition to the lack of helical preorganization, unhybridized PNAs have the tendency to fold into globular structures due to solvophobic effect. This phenomenon has been exploited in the development of ‘stemless’ PNA molecular beacons, taking advantage of the proximity of the two termini in the unhybridized state.^{38–40} However, in the case of γ GPNA1 through 5, we observed distinct CD signals, with the characteristic pattern of a right-handed helix^{41,42}—with maxima at 220 and 260 nm, and minima at 245 and 290 nm. The helical sense of this particular class of γ PNAs has been confirmed by 2D-NMR.³⁷ The amplitudes of the CD signals gradually increased with increasing number of γ GPNA units in the oligomers, showing improvements in base-stacking. Between γ GPNA3 and γ GPNA4, both with three γ -modified backbone units, γ GPNA4, which contained alternate backbone spacing, exhibited greater CD signals than γ GPNA3, which contained consecutive backbone spacing. This result is consistent with our unpublished finding which showed that nucleobases are stacked better in the alternate than in the consecutive arrangement, consistent with the “Sergeant and Soldiers” concept proposed by Green and coworkers^{43,44} to explain helical induction in polymers.

Hybridization properties

Next, we assessed the hybridization properties of PNA and γ GPNA oligomers following their hybridization with a complementary (antiparallel) DNA strand. UV-melting analysis of the corresponding duplexes revealed notable improvements in the binding affinity, on average, by $\sim 2^\circ\text{C}$ for every γ -modified backbone unit incorporated (Figure 3). This level of stabilization is significant compared to the first-generation α -GPNAs, which showed only slight improvements when they were prepared from D-amino acids with positively-charged side-chains, such as lysine or arginine,²¹ while the rest, L-amino acids in particular, had deleterious effects on the binding properties of PNA.⁴⁵ Alternate backbone spacing showed a slight enhancement in binding affinity as compared to the consecutive arrangement (compare the T_m of γ GPNA4 to that of γ GPNA3 in Figure 3). This result is consistent with the CD data which showed that the nucleobases in γ GPNA4 are better stacked with one another than those in γ GPNA3, as apparent from the amplitude of the CD signals. We attribute the enhancement in thermal stability of γ GPNA-DNA duplex, in large part, to conformational preorganization and not electrostatic interactions between guanidine and phosphate groups since PNA oligomers with (γ GPNA5) and without (PNA1) the guanidinium groups exhibited similar salt-dependent melting profiles (Figure S1, Supplemental Information). MD simulations revealed

that the lysine side-chain is too short for the guanidinium groups on γ GPNA to reach across the double helix and interact with the phosphates on the opposing DNA backbone (unpublished data).

We selected γ GPNA5 for further analysis because it contained a minimum number of guanidine groups needed to traverse the cell membrane.²¹ Inspection of Table 2 reveals that γ GPNA5 binds to (antiparallel) complementary DNA and RNA strand with significantly higher affinity than the unmodified PNA1 (+16 and +10 °C for the DNA and RNA, respectively). It is interesting to note that the T_m s of the perfectly-matched γ GPNA5-DNA and γ GPNA5-RNA are nearly identical. In the case of unmodified PNA, a PNA-RNA is generally more thermodynamically stable than a PNA-DNA duplex.^{41,46} This result indicates that γ GPNA5 are just as accommodating to RNA as they are to DNA. The sequence-mismatch selectivities of γ GPNA5 for DNA and RNA are similar to that of PNA1 (Table 2). Our data show that the positively-charged guanidinium groups in the backbone of PNAs have little influence on their sequence selectivity.

Cellular uptake

Next, we determined the uptake properties of γ GPNA6 (γ GPNA5 with TAMRA covalently-attached at the N-terminus) and compared to that of TAT transduction domain and unmodified PNA (PNA2). HeLa cells in logarithmic phase cultured in complete media were incubated separately with 1 μ M of γ GPNA6, TAT and PNA2. After 24h of incubation, cells were briefly washed three times with PBS buffer and immediately imaged without fixing. Selective uptake of γ GPNA6 and TAT was observed (Figure 4A and B), as evidenced from the fluorescent signals, while none was detected for PNA2 (Figure 4C). FACS analysis of the same cell population following identical treatment (1 μ M oligomer concentration and 24h incubation) reveals similar uptake efficiency for γ GPNA6 and TAT, which is about 2 order of magnitude higher than that for PNA2 (Figure 4D).

In a second set of experiment, live cells were incubated with the aforementioned oligomers for 24h. Following brief washing with PBS, nuclear staining dye (Hoechst-33258) was added and cells were imaged after 5-min incubation. For both γ GPNA6 (Figure 4E and F) and TAT (Figure 4G and H), the fluorescent signals appeared to localize within the vicinity of the nucleus with similar intensity—most likely in the endoplasmic reticulum (ER), where protein biosynthesis takes place. This result is similar to the observation made with the first-generation α -GPNAs.²⁰ At this point it is not clear why these cationic oligomers appear to localize specifically at the ER. One possibility is that γ GPNA5 are trapped within the ER because of the electrostatic and/or nucleobase interactions between γ GPNA5 and RNA molecules—after all, this is where most of the RNA molecules reside following their export from the nucleus. Although the cause of this ER-specific localization is still presently unknown, our result shows that the fully-alternate γ GPNA oligomer is taken up by HeLa cells just as efficient as TAT transduction domain. The fact that γ GPNA5, just like TAT domain, are localized in the ER makes them ideally suited for antisense applications.

Conclusion

In summary, we have shown that optically-pure γ GPNA monomers could be prepared from relatively cheap Boc-L-lysine by employing Mitsunobu coupling reaction. γ GPNA oligomers, unlike their aminoethylglycyl counterparts which do not have well-defined conformations, are already preorganized into a right-handed helix. These oligomers hybridize with DNA and RNA with high affinity and sequence selectivity, and are readily taken up by mammalian cells. The improved cellular uptake of γ GPNA5 could be attributed to their helical conformation, which has been shown to facilitate cellular delivery in other systems.^{47,48} Molecules that can be programmed to bind selectively to DNA and RNA, and are taken up by cells are valuable for

many applications in biology and medicine. Such molecules could be used as molecular tools to probe and manipulate nucleic acid structures and functions in cell cultures and in intact organisms, as well as therapeutic and diagnostic reagents for the treatment and detection of genetic diseases, such as cancers. Also, because of the synthetic flexibility at the γ -position, other functional groups can be incorporated in the backbone of PNA. This makes it an attractive platform for launching nucleic acid-based therapeutics and diagnostics.

Experimental Section

Boc-Lys (Guanidine-Di-Cbz)-OH (2)

To a stirred solution of NaHCO_3 (2.13 g, 25.37 mmol) in dioxane: water (1:1, 80 ml) was added Boc-Lys-OH (5 g, 20.3 mmol), followed by *N,N'* bis-*Z*-1-guanylpurazole (5.74 g, 15.2 mmol). The resulting mixture was stirred at 40 °C for 48 h. The solvent was removed under reduced pressure. The resulting residue was dissolved in ethyl acetate, washed with diluted HCl (0.3 M) and then brine, and dried over Na_2SO_4 (anhd.). The solvent was evaporated *in vacuo* and the resulting residue was purified by column chromatography and dried to give a colorless solid (9.2 g, 16.5 mmol); yield 81%. ^1H NMR (CDCl_3) δ 8.45-8.22 (br s, 1H), 7.50-7.35 (m, 10 H), 5.20-5.10 (s, 2H), 5.10-5.00 (s, 2H), 4.40-4.20 (m, 1H), 3.50-3.30 (m, 2H), 2.00-1.60 (m, 4H), 1.50-1.35 (m, 11 H); ^{13}C NMR (CDCl_3) δ 22.6, 28.3, 28.5, 32.1, 40.8, 53.2, 67.1, 68.2, 80.0, 127.9, 128.0, 128.4, 128.7, 128.8, 136.7, 153.8, 156.0, 163.6, 176.0; LRMS: 557.20; HRMS: (ESI-MS m/z) M_{calc} for $\text{C}_{28}\text{H}_{37}\text{N}_4\text{O}_8$ 557.2612, found 557.2656.

Boc-Lys (Guanidine-Di-Cbz)-ol (3)

Boc-Lys (Guanidine-Di-Cbz)-OH (2) (5 g, 8.9 mmol) was dissolved in 10 ml DME and cooled in an ice-bath. To this mixture was added NMM (0.97 ml, 8.9 mmol) drop-wise, followed by isobutyl-chloroformate (1.2 ml, 8.9 mmol). The reaction mixture was stirred in the ice-bath for another 0.5 h. The solution was filtered, and the precipitate was washed with DME (2×10 ml). To the filtrate, NaBH_4 (0.505 g, 13.3 mmol, in 10 ml water) was added at 0 °C. The aqueous layer was extracted several times with ethyl acetate and the combined organic layers were washed with brine, dried over Na_2SO_4 (anhd.). The solvent was evaporated *in vacuo* to obtain a sticky liquid. The crude product was purified by column chromatography and dried to afford a colorless solid (4.8 g, 8.87 mmol); yield 99%. ^1H NMR (CDCl_3) δ 8.30 (s, br, NH), 7.40-7.27 (m, 10 H), 5.17 (s, 2H), 5.12 (s, 2H), 4.64 (br s, NH), 3.62-3.40 (m, 5H), 2.16 (br s, 1H, NH), 1.70-1.55 (m, 6 H), 1.43 (s, 9H); ^{13}C NMR (CDCl_3) δ 23.2, 28.4, 28.8, 31.0, 40.7, 52.6, 65.7, 67.2, 68.2, 79.6, 127.9, 128.2, 128.4, 128.7, 128.8, 134.6, 136.7, 153.9, 156.0, 156.4, 163.7; LRMS: 543.13; HRMS: (ESI-MS m/z) M_{calc} for $\text{C}_{28}\text{H}_{39}\text{N}_4\text{O}_7$ 543.2819, found 543.2796.

Methyl N-(*O*, *P*-dinitrophenyl sulphonyl)-glycinate (4)

To a stirred solution of glycine ester (13.1 g, 93.8 mmol) in dichloromethane (100 ml) was added 2,4-dinitrobenzenesulphonyl chloride (25 g, 93.7 mmol) at room temperature. Pyridine (15 ml, 187.6 mmol) was added to the reaction mixture over a 15-min span and stirred at ambient temperature for another 0.5 h. The organic layer was washed several times with water, followed by brine and dried over Na_2SO_4 (anhd.). The solvent was evaporated *in vacuo*, and the crude product was purified by column chromatography and dried to give a yellow solid (25 g, 75 mmol); yield 80%. ^1H NMR (CDCl_3) δ 8.74 (d, $J = 2.3$ Hz, 1H), 8.55 (dd, $J_1 = 2.3$ Hz, $J_2 = 8.5$ Hz, 1H), 8.29 (d, $J = 8.5$ Hz, 1H), 4.09-4.02 (m, 4H), 1.18 (t, $J = 6.0$ Hz, 3H); ^{13}C NMR (CDCl_3) δ 14.0, 45.0, 62.1, 121.0, 127.2, 132.2, 139.8, 147.8, 149.8, 168.7; LRMS: 332.00; HRMS: (ESI-MS) M_{calc} for $\text{C}_{10}\text{H}_{10}\text{N}_3\text{O}_8\text{S}$ 332.0189, found 332.0218.

Boc-Lys((Guanidine-Di-Cbz)-Ψ[CH₂N(o,p-diNBS)])Gly-OEt (5)

To a stirred solution of *o,p*-DNBS-Gly-OEt **4** (1.55 g, 4.6 mmol), triphenyl phosphine (1.2 g, 4.6 mmol) and alcohol **3** (2.5 g, 4.6 mmol) in dry THF (20 ml) under inert atmosphere, cooled in an ice-bath, was added di-isopropylazidodicarboxylate (DIAD) (0.65 ml, 4.6 mmol) dropwise over a period of 0.5 h. The reaction mixture was allowed to warm to room temperature and stirred overnight. The solvent was evaporated *in vacuo*. The oily residue was purified by column chromatography and dried to afford a yellow solid (3 g, 3.5 mmol); yield 76%. ¹H NMR (CDCl₃) δ 8.45 (dd, *J*₁ = 2.4 Hz, *J*₂ = 8.8 Hz, 1H), 8.42 (d, *J* = 2.4 Hz, 1H), 8.40-8.23 (br s, NH), 8.22 (d, *J* = 8.5 Hz, 1H), 7.40-7.29 (m, 10H), 5.17 (s, 2H), 5.12 (s, 2H), 4.09-4.06 (m, 3H), 3.90-3.70 (m, 1H), 3.60-3.30 (m, 4H), 1.58-1.43 (m, 8H), 1.41 (s, 9H), 1.22 (t, *J* = 6.0 Hz, 3H); ¹³C NMR (CDCl₃) δ 14.0, 23.0, 28.3, 28.7, 32.2, 40.6, 47.7, 47.8, 52.3, 61.7, 67.1, 68.2, 79.9, 119.5, 126.0, 127.9, 128.2, 128.3, 128.4, 128.6, 128.7, 128.7, 128.8, 129.8, 132.3, 134.6, 136.8, 149.6, 153.9, 156.0, 163.7, 168.5; LRMS: 856.80; HRMS: (ESI-MS *m/z*) *M*_{calc} for C₃₈H₄₇N₇O₁₄S, 857.2902, found 857.2984.

Boc-Lys((Guanidine-Di-Cbz)[-Ψ(CH₂N)])Gly-OEt (6)

To a stirred solution of **5** (3.5 g, 4.08 mmol) in dichloromethane (20 ml) under inert atmosphere was added *n*-propyl amine (6.65 ml, 81.6 mmol). The resulting solution was stirred at room temperature for another 20 min. The solvent was evaporated. The crude product was purified by column chromatography and dried to afford a light yellow colored liquid (1.7 g, 3.1 mmol); yield 76%. ¹H NMR (CDCl₃) δ 8.28 (br s, NH), 7.38-7.25 (m, 10H), 5.15 (s, 2H), 5.10 (s, 2H), 4.15 (q, *J* = 7.2 Hz, 2H), 3.70-3.50 (m, 1H), 3.50-3.25 (m, 4H), 2.60 (2ABq, *J*₁ = 12.2 Hz, *J*₂ = 10.4 Hz, 2H), 1.56-1.4 (m, 7H), 1.41 (s, 9H), 1.25 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (CDCl₃) δ 14.2, 23.2, 28.4, 28.8, 32.8, 40.8, 50.3, 50.9, 52.9, 60.7, 67.1, 68.0, 79.0, 127.8, 128.1, 128.3, 128.4, 128.6, 128.7, 134.6, 136.8, 153.8, 155.8, 156.0, 163.7, 172.4; LRMS: 628.13; HRMS: (ESI-MS *m/z*) *M*_{calc} for C₃₂H₄₆N₅O₈ 628.3347, found 628.3323.

Boc-Lys(Guanidine-Di-Cbz)-PNA-Thyamine monomer ethyl ester (7a)

To a stirred solution of thymine acetic acid (0.48 g, 2.64 mmol) in dry DMF (15 ml) was added DCC (0.54 g, 2.64 mmol) and DhbtOH (0.42 g, 2.64 mmol). The resulting mixture was stirred at room temperature for another 1 h. Compound **6** (1.2 g, 2.2 mmol) dissolved in dry DMF (10 ml) was added to the reaction mixture and stirred at 40 °C for another 24 h. The solvent was removed under reduced pressure and the residue was diluted with ethyl acetate (100 ml). The ethyl acetate layer was washed with saturated solution of NaHCO₃ (100 ml), followed by 10 % KHSO₄ (100 ml). The organic layer was washed with brine (50 ml) and dried over anhydrous Na₂SO₄, and the solvent was removed *in vacuo*. The crude product was further purified by column chromatography and dried to afford a white solid (1.5 g, 1.88 mmol); yield 82%. ¹H NMR (DMSO *d*₆) δ 8.38 (br s, 1H), 7.44-7.23 (m, 10H), 7.21 (br s, 1H), 6.81-6.56 [2d (Rotamer₁, 2), * *J*₁ = *J*₂ = 9.2 Hz, 1H], 5.19 (s, 2H), 5.01 (s, 2H), 4.80-4.40 [ABq (Rot₁, *J* = 16.2 Hz), m (Rot₂), 2H], 4.39-2.88 (m, 9H), 1.73 (s, 3H), 1.58-1.39 (m, 4H), 1.33 [d (Rot₁, 2), *J* = 3.5 Hz, 9H], 1.15 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (DMSO *d*₆) δ 23.2, 28.4, 28.8, 31.0, 40.7, 52.6, 65.7, 67.2, 68.2, 79.6, 127.9, 128.2, 128.4, 128.7, 128.8, 134.6, 136.7, 153.9, 156.0, 156.4, 163.7; LRMS: 794.04; HRMS: (ESI-MS *m/z*) *M*_{calc} for C₃₉H₅₂N₇O₁₁ 794.3725, found 794.3682.

*Because of the carbonyl group in the bridge, two rotamers were formed for the monomers and the ester precursors—each with different chemical shift. Adenine ester (**7b**), Guanine ester (**7c**), Cytosine ester (**7d**) were prepared and isolated following the same procedure as outlined in the preparation of (**7a**).

Boc-Lys(Guanidine-Di-Cbz)-PNA-Adenine (Cbz) monomer ethyl ester (7b); yield 85%

¹H NMR (DMSO d₆) δ 8.60-8.56 [2d (Rot_{1,2}), *J*₁ = 2.1 Hz, *J*₂ = 1.6 Hz, 1H], 8.47-8.32 (m, 1H), 8.31-8.19 [2d (Rot_{1,2}), *J*₁ = 1.1, *J*₂ = 2.5 Hz, 1H], 7.65-7.25 (m, 15H), 6.95-6.56 [2d (Rot_{1,2}), *J*₁ = *J*₂ = 9.1 Hz, 1H], 5.42-4.90 (m, 8H), 4.60-3.70 (m, 6H), 3.56-3.37 (m, 2H), 3.07-2.91 (m, 1H), 1.59-1.41 (m, 4H), 1.35 [d (Rot_{1,2}), *J* = 2.8 Hz, 9H], 1.29-1.22 (m, 2H), 1.37 [2t (Rot_{1,2}), *J*₁ = *J*₂ = 7.04, 3H]; ¹³C NMR (DMSO d₆) δ 14.4, 23.4, 28.6, 29.7, 31.5, 32.1, 44.3, 48.5, 49.2, 52.3, 60.8, 61.7, 65.6, 66.7, 66.8, 68.0, 78.4, 123.4, 128.2, 128.4, 128.7, 128.8, 129.0, 131.9, 132.0, 135.6, 136.8, 137.3, 145.4, 149.8; LRMS: 937.13; HRMS: (ESI-MS m/z) *M*_{calc} for C₄₇H₅₇N₁₀O₁₁ 937.4208, found 937.4132.

Boc-Lys (Guanidine-Di-Cbz)-PNA-Guanine (Cbz) monomer ethyl ester (7c); yield 80%

¹H NMR (DMSO d₆) δ 8.31 (m, 1H), 7.69 [d (Rot_{1,2}), *J* = 6.5 Hz, 1H], 7.60-7.09 (m, 15 H), 6.89-6.58 [2d (Rot_{1,2}), *J*₁ = 9.5 Hz, *J*₂ = 8.3 Hz, 1H], 5.34-4.78 (m, 8H), 4.44-2.87 (m, 9H), 1.89-1.47 (m, 4H), 1.31 [d (Rot_{1,2}), *J* = 9.8 Hz, 9H], 1.22 (t, *J* = 7.0 Hz, 2H), 1.13 (t, *J* = 7.0 Hz, 3H); ¹³C NMR (DMSO d₆) δ 14.4, 23.4, 24.9, 28.6, 28.7, 31.7, 33.8, 44.1, 48.0, 48.5, 49.3, 52.2, 60.9, 61.7, 66.8, 67.6, 68.0, 78.6, 119.5, 128.5, 128.8, 128.9, 129.0, 135.6, 136.0, 137.3, 140.5, 148.1, 150.1, 153.2, 155.5, 155.7, 156.1, 163.5, 167.2, 167.7, 169.3, 169.8; LRMS: 975.27; HRMS: (ESI-MS m/z) *M*_{calc} for C₄₇H₅₆N₁₀O₁₂Na 975.3977, found 975.3817.

Boc-Lys (Guanidine-Di-Cbz)-PNA-Cytosine (Cbz) monomer ethyl ester (7d); yield 80%

¹H NMR (DMSO d₆) δ 8.38 (m, 1H), 7.87-7.74 [2d (Rot_{1,2}), *J*₁ = *J*₂ = 7.5 Hz, 1H], 7.65-7.48 (m, 1H), 7.43-7.19 (m, 15 H), 7.06-6.91 [2d (Rot_{1,2}), *J*₁ = 9.2 Hz, *J*₂ = 8.0 Hz, 1H], 5.18 (s, 2H), 5.17 (s, 2H), 4.94-4.49 [2ABq (Rot_{1,2}), *J*₁ = *J*₂ = 16.3 Hz, 2H], 4.40-2.84 (m, 9H), 1.77-1.41 (m, 4H), 1.33 [d (Rot_{1,2}), *J* = 3.8 Hz, 9H], 1.21 (t, *J* = 7.1 Hz, 2H), 1.14 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (DMSO d₆) δ 14.4, 23.2, 23.4, 28.6, 31.5, 48.6, 49.3, 49.8, 52.2, 60.9, 61.6, 66.8, 66.9, 68.0, 78.4, 94.3, 128.3, 128.5, 128.7, 128.9, 129.0, 131.8, 132.0, 135.6, 136.4, 137.4, 150.9, 153.7, 155.3, 155.5, 156.0, 163.5, 167.8, 168.2, 169.2, 169.6; LRMS: 935.39; HRMS: (ESI-MS m/z) *M*_{calc} for C₄₆H₅₆N₈O₁₂Na 935.3915, found 935.3884.

Boc-Lys (Guanidine-Di-Cbz)-PNA-Thyamine monomer acid (8a)

To a stirred solution of **7a** (0.5 g, 6.3 mmol) in THF (10 ml), 2N NaOH (10 ml) was added drop-wise at 0 °C over a period of 15 min. The resulting mixture was stirred at same temperature for another 0.5 h. At the end of the reaction, as monitored by TLC, H₂O (20 ml) was added. The reaction mixture was extracted with ethyl acetate (2×25 ml). The combined aqueous layers were acidified with 5 % HCl (to pH 4) at 0 °C and then extracted with ethyl acetate (4×25 ml). The combined organic layers were dried over Na₂SO₄ (anhd.) and the solvent was evaporated *in vacuo*. The crude product was purified by column chromatography and dried to afford a colorless solid (0.35 g, 4.5 mmol); yield 72%. ¹H NMR (DMSO d₆) δ 8.39 (m, 1H), 7.43-7.23 (m, 10 H), 7.18 (br s, 1H), 6.80-6.60 [2d (Rot_{1,2}), *J*₁ = 8.2 Hz, *J*₂ = 7.4 Hz, 1H], 5.18 (s, 2H), 5.00 (s, 2H), 4.71-4.31 [ABq (Rot_{1,2}, *J* = 17.2 Hz), m (Rot₂), 2H], 3.94-2.60 (m, 7H), 1.7 (s, 3H), 1.55-1.36 (m, 3H), 1.32 (s, 9H), 1.29-1.10 (m, 3H); ¹³C NMR (DMSO d₆) δ 12.4, 23.4, 28.7, 31.9, 48.1, 48.9, 49.2, 51.7, 52.2, 66.8, 68.0, 77.9, 78.2, 108.4, 128.2, 128.4, 128.7, 129.0, 135.6, 137.3, 142.6, 151.5, 153.1, 155.4, 156.0, 163.4, 164.8, 168.3; LRMS 766.27; HRMS: (ESI-MS m/z) *M*_{calc} for C₃₇H₄₈N₇O₁₁ 766.3412, found 766.3429.

PNA monomer Adenine (Cbz) acid (**8b**), Guanine ester(Cbz) acid (**8c**) and Cytosine (Cbz) acid (**8d**) were prepared and isolated following the same procedure as outlined in the preparation of (**8a**) above.

Boc-Lys (Guanidine-Di-Cbz)-PNA-Adenine (Cbz) monomer acid (8b); yield 75%

^1H NMR (DMSO d_6) δ 8.55 [d (Rot_{1,2}), J = 5.2 Hz, 1H], 8.37 (br s, 1H), 8.23 [d (Rot_{1,2}) J = 11.8 Hz, 1H], 7.47-7.21 (m, 15 H), 6.96-6.61 [2d (Rot_{1,2}) J_1 = 9.5 Hz, J_2 = 7.9 Hz, 1H], 5.30-4.90 (m, 9H), 4.04-2.68 (m, 7H), 1.55-1.37 (m, 3H), 1.28 (s, 9H), 1.26-1.16 (m, 3H); ^{13}C NMR (DMSO d_6) δ 23.4, 28.7, 31.9, 44.5, 49.3, 51.9, 63.3, 66.7, 66.8, 68.0, 77.9, 123.3, 126.8, 127.0, 128.3, 128.4, 128.7, 128.8, 129.0, 135.6, 136.8, 137.4, 145.7, 149.7, 151.7, 152.6, 153.1, 155.4, 155.9, 163.4, 166.5, 167.6; LRMS: 909.00; HRMS: (ESI-MS m/z) M_{calc} for $\text{C}_{45}\text{H}_{53}\text{N}_{10}\text{O}_{11}$ 909.3895, found 909.3897.

Boc-Lys (Guanidine-Di-Cbz)-PNA-Guanine (Cbz) monomer acid (8c); yield 68%

^1H NMR (DMSO d_6) δ 8.39 (m, 1H), 7.72 [d (Rot_{1,2}) J = 5.2 Hz, 1H], 7.43-7.26 (m, 15H), 6.91-6.61 [2d (Rot_{1,2}), J_1 = 9.8 Hz, J_2 = 8.0 Hz, 1H], 5.22 (s, 2H), 5.15-4.78 (m, 4H), 4.19-2.85 (m, 7H), 1.58-1.37 (m, 3H), 1.31 [d (Rot_{1,2}), J = 6.1 Hz, 9H], 1.25-1.12 (m, 3H); ^{13}C NMR (DMSO d_6) δ 23.3, 23.4, 28.6, 28.7, 31.7, 44.2, 49.1, 66.8, 67.5, 67.6, 68.0, 78.0, 78.5, 119.5, 119.6, 128.2, 128.3, 128.6, 128.7, 128.8, 135.6, 135.9, 136.0, 137.3, 147.6, 147.7, 150.0, 153.2, 154.9, 155.0, 155.5, 155.6, 156.1, 163.4, 166.9, 167.6; LRMS: 925.13; HRMS: (ESI-MS m/z) M_{calc} for $\text{C}_{45}\text{H}_{53}\text{N}_{10}\text{O}_{12}$ 925.3845, found 925.3860.

Boc-Lys (Guanidine-Di-Cbz)-PNA-Cytosine (Cbz) monomer acid (8d); yield 70%

^1H NMR (DMSO d_6) 8.38 (br s, 1H), 7.80 (d, J = 7.5 Hz, 1H), 7.47-7.21 (m, 15 H), 6.97 (d, J = 7.3 Hz, 1H), 6.85-6.60 [2d (Rot_{1,2}), J_1 = 11.1 Hz, J_2 = 6.4 Hz, 1H], 5.17 (br s, 4H), 5.00 (s, 2H), 4.88-4.89 [ABq (Rot₁, J = 16.3 Hz), m (Rot₂), 2H], 3.98-2.68 (m, 7H), 1.56-1.36 (m, 3H), 1.32 (s, 9H), 1.29-1.10 (m, 3H); ^{13}C NMR (DMSO d_6) 23.4, 28.7, 31.9, 41.0, 49.0, 49.4, 50.1, 51.7, 52.3, 66.8, 66.9, 68.0, 77.9, 78.3, 94.4, 128.2, 128.3, 128.4, 128.6, 128.7, 128.9, 129.0, 135.6, 136.4, 137.3, 151.0, 151.4, 153.1, 153.6, 155.4, 155.9, 156.0, 163.4, 167.1, 168.1; LRMS: 885.40; HRMS: (ESI-MS m/z) M_{calc} for $\text{C}_{44}\text{H}_{53}\text{N}_8\text{O}_{12}$ 885.3783, found 885.3871.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

We thank Eric J. Lanni for his assistance with high resolution MS and Chakicherla Gayathri with NMR. Financial supports were provided by National Institutes of Health to D.H.L. (GM076251-01), K.L. (EY08098) and S.M.T (5P50 CA097190-04); and Applied Biosystems and The Mellon College of Sciences to B.S.

References

1. De Mesmaeker A, Haner R, Martin P, Moser HE. *Acc Chem Res* 1995;28:366–374.
2. Wengel J. *Acc Chem Res* 1999;32:301–310.
3. Nielsen PE. *Acc Chem Res* 1999;32:624–630.
4. Summerton JE. *Lett Pept Sci* 2004;10:215–236.
5. Juliano RJ, Yoon H. *Curr Opin Mol Therap* 2000;2:297–303. [PubMed: 11249624]
6. Lebedeva I, Benimetskaya L, Stein CA, Vilenchik M. *Eur J Pharm Biopharm* 2000;50:101–119. [PubMed: 10840195]
7. Stein CA. *Nat Biotech* 1999;17:209–209.
8. Nielsen PE, Egholm M, Berg RH, Buchardt O. *Science* 1991;254:1497–1500. [PubMed: 1962210]
9. Nielsen PE. *Mol Biotech* 2004;26:233–248.
10. Nielsen PE. *Q Rev Biophys* 2005;38:345–350. [PubMed: 16600055]
11. Koppelhus U, Nielsen PE. *Adv Drug Deliv Rev* 2003;55:267–280. [PubMed: 12564980]
12. Frankel AD, Pabo CO. *Cell* 1988;55:1189–1193. [PubMed: 2849510]

13. Green M, Loewenstein PM. *Cell* 1988;55:1179–1188. [PubMed: 2849509]
14. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF. *Science* 1999;285:1569–1572. [PubMed: 10477521]
15. Gratton JP, Yu J, Griffith JW, Babbitt RW, Scotland RS, Hickey R, Giordano FJ, Sessa WC. *Nat Med* 2003;9:357–362. [PubMed: 12598894]
16. Lewin M, Carlesso N, Tung CH, Tang XW, Cory D, Scadden DT, Weissleder R. *Nat Biotech* 2000;18:410–414.
17. Wender PA, Mitchell DJ, Pattabiraman K, Pelkey ET, Steinman L, Rothbard JB. *Proc Natl Acad Sci USA* 2000;97:13003–13008. [PubMed: 11087855]
18. Umezawa N, Gelman MA, Haigis MC, Raines RT, Gellman SH. *J Am Chem Soc* 2002;124:368–369. [PubMed: 11792194]
19. Zhou P, Wang M, Du L, Fisher GW, Waggoner A, Ly DH. *J Am Chem Soc* 2003;125:6878–6879. [PubMed: 12783535]
20. Zhou P, Dragulescu-Andrasi A, Bhattacharya B, O'keefe H, Vatta P, Hyldig-Nielsen JJ, Ly DH. *Bioorg Med Chem Lett* 2006;16:4931–4935. [PubMed: 16809033]
21. Dragulescu-Andrasi A, Zhou P, He G, Ly DH. *Chem Comm* 2005:244–246. [PubMed: 15724200]
22. Zasloff M. *Nature* 2002;415:389–395. [PubMed: 11807545]
23. Dragulescu-Andrasi A, Rapireddy S, He G, Bhattacharya B, Hyldig-Nielsen JJ, Zon G, Ly DH. *J Am Chem Soc* 2006;128:16104–16112. [PubMed: 17165763]
24. Kosynkina L, Wang W, Liang TC. *Tetrahedron Lett* 1994;35:5173–5176.
25. Wu Y, Xu JC. *Tetrahedron* 2001;57:8107–8113.
26. Englund EA, Appella DH. *Org Lett* 2005;7:3465–3467. [PubMed: 16048318]
27. Tedeschi T, Sforza S, Corradini R, Marchelli R. *Tetrahedron Lett* 2005;46:8395–8399.
28. Dose C, Seitz O. *Org Lett* 2005;7:4365–4368. [PubMed: 16178534]
29. Englund EA, Appella DH. *Angew Chem Int Ed* 2007;46:1414–1418.
30. Falkiewicz B, Kolodziejczyk AS, Liberek B, Wisniewski K. *Tetrahedron* 2001;57:7909–7917.
31. Stanfield CF, Parker JE, Kanellis P. *J Org Chem* 1981;46:4797–7898.
32. Rittle KE, Homnick CF, Ponticello GS, Evans BE. *J Org Chem* 1982;47:3016–3018.
33. Dueholm KL, Egholm M, Behrens C, Christensen L, Hansen HF, Vulpius T, Petersen KH, Berg RH, Nielsen PE, Buchardt O. *J Org Chem* 1994;59:5767–5773.
34. Seco JM, Quinoa E, Riguera R. *Chem Rev* 2004;104:17–118.
35. Christensen L, Fitzpatrick R, Gildea B, Petersen KH, Hansen HF, Koch T, Egholm M, Buchardt O, Nielsen PE, Coull J, Berg RH. *J Pept Sci* 1995;1:175–183. [PubMed: 9222994]
36. Sen S, Nilsson L. *J Am Chem Soc* 2001;123:7414–7422. [PubMed: 11472173]
37. Dragulescu-Andrasi A, Rapireddy S, Frezza BM, Gayathri C, Gil RR, Ly DH. *J Am Chem Soc* 2006;128:10258–10267. [PubMed: 16881656]
38. Seitz O. *Angew Chem Int Ed* 2000;39:3249–3252.
39. Ranasinghe RT, Brown LJ, Brown T. *Chem Comm* 2001:1480–1481.
40. Kuhn H, Demidov VV, Coull JM, Fiandaca MJ, Gildea BD, Frank-Kamenetskii MD. *J Am Chem Soc* 2002;124:1097–1103. [PubMed: 11829619]
41. Egholm M, Buchardt O, Christensen L, Behrens C, Freier SM, Driver DA, Berg RH, Kim SK, Norden B, Nielsen PE. *Nature* 1993;365:566–568. [PubMed: 7692304]
42. Wittung P, Nielsen PE, Buchardt O, Egholm M, Norden B. *Nature* 1994;368:561–563. [PubMed: 8139692]
43. Green MM, Peterson NC, Sato T, Teramoto A, Cook R, Lifson S. *Science* 1995;268:1860–1866. [PubMed: 17797527]
44. Green MM, Cheon KS, Yang SY, Park JW, Swansburg S, Liu W. *Acc Chem Res* 2001;34:672–680. [PubMed: 11513575]
45. Haaime G, Lohse A, Buchardt O, Nielsen PE. *Angew Chem Int Ed* 1996;35:1939–1942.
46. Jensen KK, Orum H, Nielsen PE, Norden B. *Biochemistry* 1997;36:5072–5077. [PubMed: 9125529]
47. Wimley WC, White SH. *Biochemistry* 2000;39:4432–4442. [PubMed: 10757993]

48. Potocky TB, Menon AK, Gellman SH. J Am Chem Soc 2005;127:3686–3687. [PubMed: 15771489]

Figure 1. ^{19}F -NMR spectra of thymine-containing γ GPNA monomers prepared from L-(left) and D-lysine (right) following the removal of Boc-protecting group and coupling with MTPA-Cl.

Figure 2.

CD spectra of individual (single-stranded) PNA and γ GPNA oligomers. All samples were prepared in buffer containing 10mM sodium phosphate, 100mM NaCl and 0.1 mM EDTA at 5 μ M strand concentration each. *Inset:* UV-absorbance of each sample recorded at 90 °C showing that the amount of PNA and γ GPNA in each sample was virtually the same.

Figure 3.

First-derivatives of the PNA-DNA and γ GPNA-DNA UV-melting profiles. The hybrid duplexes were prepared by mixing stoichiometric amount ($2\mu\text{M}$ strand concentration) of each oligomer in the same buffer used in CD measurements and annealed by incubating at $90\text{ }^{\circ}\text{C}$ for 5 min, followed by gradual cooling to room temperature. UV-absorbance at 260 nm was monitored as a function of temperature from 20 to $90\text{ }^{\circ}\text{C}$ at the rate of $1^{\circ}\text{C}/\text{minute}$.

Figure 4.

A–C: Superimposed DIC and fluorescent images of HeLa cells after incubation with 1 μ M of γ GPNA6, TAT and PNA2, respectively, for 24h. Cells were washed 3 times with PBS and immediately imaged (these were live cells). **D:** FACS analysis of HeLa cells following incubation with the same oligomer concentration and period (20,000 cells were taken for the events). **E and G:** Fluorescent images of HeLa cells incubated with 1 μ M of γ GPNA6 and TAT, respectively, for 24h, followed by brief washing with PBS and incubation with Hoechst (1mg/ml) in fresh growth media for 5-min. Blue: nucleus (Hoechst), red: oligomers (TAMRA). **F and H:** Bright field images of panel E and G, respectively.

Scheme 1.
Synthesis of γ GPNA monomers

Scheme 2. Derivatization of γ GPNA monomer for ^{19}F -NMR analysis

Table 1

Sequence of the oligomers used in this study along with their M.W.

Oligomers	Sequence	Cal. M.W.(found)	% Yield ^a
PNA1	H-GCATGTTTGA- ^L Lys-NH ₂	2886.8 (2885.8)	35
γGPNA1	H-GCATG <u>T</u> TTGA-NH ₂	2869.1 (2874.3)	32
γGPNA2	H-GCATG <u>TT</u> TGA-NH ₂	2982.2 (2991.2)	37
γGPNA3	H-GCATG <u>TTT</u> TGA-NH ₂	3095.3 (3098.5)	33
γGPNA4	H-GCATG <u>T</u> <u>T</u> TGA-NH ₂	3095.3 (3098.9)	27
γGPNA5	H-G <u>C</u> ATGTTTGA-NH ₂	3321.5 (3325.8)	31
γGPNA6	TAMRA-G <u>C</u> ATG <u>T</u> TTGA-NH ₂	3825.7 (3824.6)	29
PNA2	TAMRA-GCATGTTTGA- ^L Lys-NH ₂	3355.2 (3378.8)	33
TAT	TAMRA-YGRKKRRQRRR-NH ₂	1972.2 (1973.2)	40

Underlined sequence denotes γGPNA backbone modification.

^a After purification.

Table 2
Sequence discrimination of PNA1 and γ GPNA5 for DNA and RNA

	PNA1			
	γ GPNA5			
	DNAX			
	RNAX			
	H-GCATGTTTGA- ¹ Lys-NH ₂			
	H-GCATGTTTGA-NH ₂			
	3'-CGTACXAACCT-5'			
	3'-CGUACXAACU-5'			
	PNA1-DNAX	γ GPNA5-DNAX	PNA1-RNAX	γ GPNA5-RNAX
X=A, PM	43 °C	59 °C	50 °C	60 °C
X=C, T<>C MM	25 (-18)	39 (-20)	33 (-17)	40 (-20)
X=G, T<>G MM	25 (-18)	40 (-19)	40 (-10)	48 (-12)
X=T, T<>T MM	32 (-11)	40 (-19)	39 (-11)	49 (-11)

PM: perfect match, MM: mismatch. The duplex concentration is 2 μ M prepared in the same buffer used in CD measurements.